Synthaverse S.A.

SVE

PLBMDLB00018

Pharmaceuticals

Market Closed - Warsaw S.E. Other stock markets 16:55:55 24/05/2024 BST			5-day change	1st Jan Change
4.92 ^PLN	+0.41%		-2.57%	+15.22%

04-10	Synthaverse S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Synthaverse S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment Arm

May 03, 2021

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced a private placement of 1,734,798 common shares at a price of PLN 12.33 per share for gross proceeds of PLN 21,390,059.34 on May 4, 2021. The transaction will include participation from Ipopema Securities S.A., Investment Arm.

Latest news about Synthaverse S.A.

Synthaverse S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	04-10	CI
Synthaverse S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-22	CI
Synthaverse S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	20/09/23	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will Change its Ticker to SVE from BML	18/07/23	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will Change its Name to SYNTHAVERSE S.A	18/07/23	CI
BIOMED-LUBLIN WytwÃ³rnia Surowic i Szczepionek S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/05/23	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	20/04/23	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	07/11/22	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.(WSE:BML) dropped from S&P Global BMI Index	19/09/22	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	07/09/22	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/05/22	CI
BIOMED-LUBLIN Wytw?rnia Surowic i Szczepionek S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	09/11/21	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 13.398489 million in funding	26/09/21	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	31/08/21	CI
Biomed-Lublin Wytwórnia Surowic I Szczepionek S.A. Announces Earnings Results for the First Quarter of 2021	28/05/21	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment Arm	03/05/21	CI
Biomed-Lublin Wytwórnia Surowic I Szczepionek S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	02/03/21	CI
Biomed-Lublin Secures PLN 29.2 Million in EU Financing for Construction of an R&D Center	01/10/20	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.(WSE:BML) added to S&P Global BMI Index	21/09/20	CI
BIOMED LUBLIN Announces Earnings Results for the First Half Year 2020	15/09/20	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 6.826041 million in funding	06/07/20	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced a financing transaction	27/06/19	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it has received PLN 4.8 million in funding	22/07/18	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 4.8 million in funding	30/11/17	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek Spólka Akcyjna announced that it expects to receive PLN 4.01 million in funding	13/11/17	CI

Chart Synthaverse S.A.

Duration

Period

More charts

Company Profile

Synthaverse SA formerly known as Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company operating in the Life Science industry, dealing primarily with the production of medicines. The Company focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The Company offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The Company supplies its products to 50 countries around the world.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
SYNTHAVERSE S.A.	+15.22%	88.46M
CSL LIMITED	-2.00%	90.02B
SAMSUNG BIOLOGICS CO.,LTD.	-1.18%	39.15B
BIOGEN INC.	-15.83%	31.71B
UCB	+62.86%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-21.68%	14.34B
INCYTE CORPORATION	-8.73%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.05%	11.18B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-45.69%	10.97B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.94B